comparemela.com

Latest Breaking News On - Silverarc capital management - Page 5 : comparemela.com

Clene (NASDAQ:CLNN) Stock Rating Reaffirmed by Benchmark

Benchmark reissued their buy rating on shares of Clene (NASDAQ:CLNN – Free Report) in a report issued on Thursday morning, Benzinga reports. Benchmark currently has a $5.00 price objective on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Clene in a research note on Wednesday, […]

Silverarc-capital-management
Nasdaq
Clene-inc
Securities-exchange-commission
Clene-company-profile
Free-report
Get-free-report
Capital-management
Multiple-sclerosis
Clene-daily

Poseida Therapeutics' (PSTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q2 2024 earnings at ($0.43) EPS, Q3 2024 earnings at ($0.46) EPS, […]

Ohio
United-states
Mirae-asset-global-investments-co
Poseida-therapeutics-inc
Silverarc-capital-management
Nasdaq
Barclays-plc
Poseida-therapeutics
Free-report
Get-free-report
Capital-management

Aerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by Wedbush

Wedbush reiterated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $41.00 price target on the stock. Other analysts also recently issued reports about the stock. Jefferies Financial Group initiated coverage on shares of Aerovate Therapeutics in […]

Alps
Switzerland-general
Switzerland
United-states
Swiss
Hunter-gillies
Georgea-eldridge
Silverarc-capital-management
Securities-exchange-commission
Nasdaq
Aerovate-therapeutics-inc
Alps-advisors-inc

Compugen (NASDAQ:CGEN) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a research report report published on Tuesday. Separately, Truist Financial cut their price target on Compugen from $5.00 to $4.00 and set a buy rating for the company in a research note on Tuesday. View Our Latest […]

Israel
United-states
Compugen-ltd
Kingsview-wealth-management
Compugen
Silverarc-capital-management
Free-report
Truist-financial
Get-free-report
Bay-capital-management
Wealth-management

Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

China
Piper-sandler
Raymond-james
Scholar-rock-company-profile
Nasdaq
Silverarc-capital-management
Scholar-rock-holding-corporation
China-universal-asset-management-co
Walleye-trading
Scholar-rock-holding-co
Scholar-rock-holding
Get-free-report
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.